Skip to main content
. 2016 May 1;101(5):2056–2062. doi: 10.1210/jc.2015-4202

Figure 2.

Figure 2.

A, HR for the development of diabetes in subjects with IGT who participated in the post-treatment follow-up period (median, 11.4 mo). B, Cumulative HR for the development of diabetes in subjects with IGT from the time of randomization until the end of post-treatment follow-up period.